4.6 Article

Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis

期刊

MEDICAL JOURNAL OF AUSTRALIA
卷 196, 期 3, 页码 193-197

出版社

WILEY
DOI: 10.5694/mja11.10731

关键词

-

资金

  1. sanofi-aventis (Paris, France)
  2. Bristol-Myers Squibb (Princeton, New Jersey, USA)
  3. Waksman Foundation (Tokyo, Japan)
  4. AstraZeneca
  5. Bristol-Myers Squibb
  6. Eisai
  7. Ethicon
  8. Heartscape
  9. sanofi-aventis
  10. Servier Australia
  11. Pfizer
  12. SmithKline Beecham
  13. Bayer
  14. Merck Sharpe and Dohme
  15. Servier Laboratories
  16. Abbott Pharmaceuticals
  17. Pfizer Australia
  18. Boehringer Ingelheim
  19. GlaxoSmithKline
  20. Medtronic
  21. Nycomed
  22. Astellas
  23. Endotis Pharma
  24. Servier
  25. Medicines Company

向作者/读者索取更多资源

Objective: To report on 1-year cardiovascular (CV) event rates in patients with established cardiovascular disease (CVD) or with multiple cardiovascular risk factors. Design, patients and setting: Prospective cohort study of 2873 patients at high risk of atherothrombosis based on the presence of multiple risk factors and overt coronary artery disease (CAD), cerebrovascular disease (CerVD) or peripheral arterial disease (PAD) presenting to 273 Australian general practitioners; this study was conducted as part of the international REACH Registry. Main outcome measures: One-year rates of cardiovascular death, myocardial infarction, stroke, and hospitalisation for cardiovascular procedures. Results: The cardiovascular death rate at 1 year was 1.4%. The combined cardiovascular death, non-fatal MI, stroke and hospitalisation rate for vascular disease affecting one location at 1 year was 11%. Even for patients with no overt disease, but with multiple risk factors, the 1-year combined event rate was 4.2%. The highest combined event rate was in patients with PAD (21.0%), and in patients with atherothrombotic disease identified in all three locations (coronary arteries, cerebrovascular system and peripheral arteries) at 39%. Conclusion: The rate of clinical events in community-based patients with stable atherothrombotic disease increases dramatically with the severity of disease and the number of vascular beds involved. Where disease was evident in all three locations, and for patients with PAD alone, the 1-year risk of cardiovascular events was substantially increased. Poor adherence to statin therapy in the secondary preventive setting is a major treatment gap that needs to be closed; the influences of obesity and diabetes warrant further investigation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据